IC
MLYS icon

Ikarian Capital’s Mineralys Therapeutics MLYS Stock Holding History

Ikarian Capital’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-200,000
Closed -$7.26M – 192
2025
Q4 		$7.26M Buy
+200,000
New +$8.02M 0.57% 51
2025
Q1 		– Sell
-332,390
Closed -$3.82M – 196
2024
Q4 		$4.09M Buy
332,390
+152,390
+85% +$1.99M 0.56% 52
2024
Q3 		$2.18M Buy
+180,000
New +$2.18M 0.3% 72

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Ikarian Capital's MLYS Position: Q1 2026 in Review

Ikarian Capital sold out of Mineralys Therapeutics (MLYS) in Q1 2026, closing a stake of 200,000 shares — an estimated $7.26M sold.

Ikarian Capital first reported a position in MLYS in Q3 2024 and held it in 3 quarters. The position peaked at $7.26M in Q4 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Ikarian Capital reported no remaining Mineralys Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Ikarian Capital sold 200,000 Mineralys Therapeutics shares in Q1 2026, an estimated $7.26M.
  • Ikarian Capital first reported a position in Mineralys Therapeutics in Q3 2024 and held it in 3 quarters.
  • Ikarian Capital's Mineralys Therapeutics position peaked at $7.26M in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.